Synthesis and Biological Evaluation of BODIPY-PF-543
by
Jitendra Shrestha 1,†, Gil Tae Hwang 2,†
, Taeho Lee 3, Seon Woong Kim 1, Yoon Sin Oh 4, Yongseok Kwon 5, Seung Woo Hong 2, Sanghee Kim 6, Hong Seop Moon 1, Dong Jae Baek 1,* and Eun-Young Park 1,*
Jitendra Shrestha 1,†, Gil Tae Hwang 2,†, Taeho Lee 3, Seon Woong Kim 1, Yoon Sin Oh 4, Yongseok Kwon 5, Seung Woo Hong 2, Sanghee Kim 6, Hong Seop Moon 1, Dong Jae Baek 1,* and Eun-Young Park 1,*
1
College of Pharmacy, Mokpo National University, Jeonnam 58554, Korea
2
Department of Chemistry, Kyungpook National University, Daegu 41566, Korea
3
College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea
4
Department of Food and Nutrition, Eulji University, Seongnam 13135, Korea
5
Department of Chemistry, Sogang University, Seoul 04107, Korea
6
College of Pharmacy, Seoul National University, Seoul 08826, Korea
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2019, 24(23), 4408; https://doi.org/10.3390/molecules24234408
Received: 24 October 2019 / Revised: 29 November 2019 / Accepted: 30 November 2019 / Published: 2 December 2019
Sphingosine-1-phosphate (S1P) regulates the proliferation of various cells and promotes the growth of cancer cells. Sphingosine kinase (SK), which transforms sphingosine into S1P, has two isotypes: SK1 and SK2. To date, both isotypes are known to be involved in the proliferation of cancer cells. PF-543, an SK1 inhibitor developed by Pfizer, strongly inhibits SK1. However, despite its strong SK1 inhibitory effect, PF-543 shows low anticancer activity in vitro. Therefore, additional biological evidence on the anticancer activity of SK1 inhibitor is required. The present study aimed to investigate the intracellular localization of PF-543 and identify its association with anticancer activity by introducing a fluoroprobe into PF-543. Boron–dipyrromethene (BODIPY)-introduced PF-543 has a similar SK1 inhibitory effect as PF-543. These results indicate that the introduction of BODIPY does not significantly affect the inhibitory effect of SK1. In confocal microscopy after BODIPY-PF-543 treatment, the compound was mainly located in the cytosol of the cells. This study demonstrated the possibility of introducing fluorescent material into an SK inhibitor and designing a synthesized compound that is permeable to cells while maintaining the SK inhibitory effect.
View Full-Text
Keywords:
sphingosine kinase; PF-543; BODIPY; inhibitor; confocal microscopy
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Shrestha, J.; Hwang, G.T.; Lee, T.; Kim, S.W.; Oh, Y.S.; Kwon, Y.; Hong, S.W.; Kim, S.; Seop Moon, H.; Baek, D.J.; Park, E.-Y. Synthesis and Biological Evaluation of BODIPY-PF-543. Molecules 2019, 24, 4408.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
- Supplementary File 1:
PDF-Document (PDF, 227 KB)
